. 2016 Dec 15;12(1):111–121. doi: 10.1007/s11523-016-0472-3

Table 4.

Acceleration factors calculated by fitting the Weibull and generalized gamma models to the observational datasets in the PREVAIL trial (two-stage method)

Parametric model	Treatment arm	Acceleration factor (95% CI)^a	Diagnostic criteria
Parametric model	Treatment arm	Acceleration factor (95% CI)^a	AIC	BIC
Weibull	Enzalutamide	1.76 (1.24–2.49)	1087.36	1176.12
Weibull	Placebo	1.30 (0.96–1.76)	1469.01	1566.96
Generalized gamma	Enzalutamide	1.13 (0.83–1.54)	868.20	961.19
Generalized gamma	Placebo	1.35 (0.99–1.85)	1468.78	1571.40

AIC Akaike information criterion, BIC Bayesian information criterion, CI confidence interval

^aAn acceleration factor of >1.0 indicates a treatment benefit associated with switching